Literature DB >> 35182735

Defining clinical outcome pathways.

Daniel Korn1, Andrew J Thieme2, Vinicius M Alves2, Michael Yeakey3, Joyce V V B Borba2, Stephen J Capuzzi2, Karamarie Fecho4, Chris Bizon4, Stephen W Edwards5, Rada Chirkova6, Christine M Colvis7, Noel T Southall6, Christopher P Austin6, Eugene N Muratov8, Alexander Tropsha9.   

Abstract

Here, we propose a broad concept of 'Clinical Outcome Pathways' (COPs), which are defined as a series of key molecular and cellular events that underlie therapeutic effects of drug molecules. We formalize COPs as a chain of the following events: molecular initiating event (MIE) → intermediate event(s) → clinical outcome. We illustrate the concept with COP examples both for primary and alternative (i.e., drug repurposing) therapeutic applications. We also describe the elucidation of COPs for several drugs of interest using the publicly accessible Reasoning Over Biomedical Objects linked in Knowledge-Oriented Pathways (ROBOKOP) biomedical knowledge graph-mining tool. We propose that broader use of COP uncovered with the help of biomedical knowledge graph mining will likely accelerate drug discovery and repurposing efforts.
Copyright © 2022. Published by Elsevier Ltd.

Entities:  

Keywords:  Clinical outcome pathways; Drug repurposing; Key molecular events; Knowledge graphs

Mesh:

Year:  2022        PMID: 35182735     DOI: 10.1016/j.drudis.2022.02.008

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  1 in total

Review 1.  Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.

Authors:  Laure-Alix Clerbaux; Maria Cristina Albertini; Núria Amigó; Anna Beronius; Gillina F G Bezemer; Sandra Coecke; Evangelos P Daskalopoulos; Giusy Del Giudice; Dario Greco; Lucia Grenga; Alberto Mantovani; Amalia Muñoz; Elma Omeragic; Nikolaos Parissis; Mauro Petrillo; Laura A Saarimäki; Helena Soares; Kristie Sullivan; Brigitte Landesmann
Journal:  J Clin Med       Date:  2022-07-31       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.